Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicoderm C-Q Gum
- Development stage
- Phase 4
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Buccal
01
Overview
Nicoderm C-Q Gum is a brand of nicotine replacement therapy (NRT) in chewing gum form, primarily used as an aid for smoking cessation. Its active ingredient, nicotine polacrilex, is a complex of nicotine bound to an ion-exchange resin, designed to provide a controlled release of nicotine. This helps to alleviate nicotine withdrawal symptoms and reduce cravings, supporting individuals in their efforts to quit smoking.
- Brand names
- Nicoderm C-Q GumNicoderm CQ
- Other names
- nicotine polacrilex gumnicotine gum
02
Targets
α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)
Beyond the preview
Go deeper on Nicoderm C-Q Gum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nicoderm C-Q Gum.